Top Story Today
BMS Bets $15 Billion on China's Drug Pipeline While Congress Sharpens Its Scissors
Bristol Myers Squibb locked in a 13-program mega-collaboration with China's Hengrui worth up to $15.2 billion, making it the largest China-to-global biopharma deal in history. The real cash outlay is far more modest: $600 million upfront, with the remaining $14.3 billion in milestone payments that only hit if the drugs actually work. BMS gets rights outside mainland China, Hong Kong SAR, and Macau SAR to four oncology assets while outsourcing risky early-stage development to China's faster, cheaper clinical trial machine. The deal lands as Congress debates new legislation that could pull exactly these kinds of transactions into national security review.
Why it matters: With over 60% of BMS's pipeline already sourced externally and patent cliffs looming, this deal crystallizes Big Pharma's deepening dependence on Chinese innovation at precisely the moment Washington is building new walls around it.
Read more →Deals and M&A
Novartis Paid $1.1 Billion for a Drug That's Never Been Tested in Humans
Novartis dropped $1.1 billion in upfront cash on Myricx Bio, a UK startup with zero clinical data, for a completely novel antibody-drug conjugate payload class. The NMT inhibitor warheads attack cancer through a mechanism no existing ADC uses, potentially working where current treatments fail due to resistance. About 73% of the deal's total $1.5 billion value is guaranteed at closing, a stunning level of conviction for preclinical assets.
Read more →Lilly Bets $2.3 Billion That a Disgraced Drug Class Deserves Redemption
Eli Lilly is acquiring Ajax Therapeutics for up to $2.3 billion, chasing a next-gen JAK2 inhibitor with 780-fold selectivity over JAK1. Early data showed 70% response rates in myelofibrosis patients who had already failed existing treatments, with zero dose-limiting toxicities. For a drug class still carrying an FDA black box warning, the clean safety signal is what's turning heads.
Read more →Ipsen Drops $2.5 Billion in Five Days on Two Rare Disease Bets
French pharma Ipsen announced back-to-back acquisitions in a single week: Kartos Therapeutics (blood cancer, up to $1.75 billion) and Memo Therapeutics (a first-in-class antibody for a transplant-destroying virus with zero approved treatments, roughly $800 million). The deals signal Ipsen's sprint to become a rare disease powerhouse, with most of the consideration tied to milestones.
Read more →AstraZeneca Spends $30M for a Shot at $1.77B in Kidney Disease Drugs
AstraZeneca's latest deal with China's CSPC targets kidney disease using siRNA technology that can reach beyond the liver. The $30 million upfront buys an option on up to $1.77 billion in milestone value, a masterclass in structured risk. The deal's geographic split (global vs. ex-China rights) reads like a geopolitical playbook for cross-border pharma in 2026.
Read more →Clinical Breakthroughs
Legend Biotech Goes 6 for 6 With a CAR-T That Builds Itself Inside Patients
Legend Biotech's in vivo CAR-T therapy hit a perfect 100% response rate in six lymphoma patients at the higher dose, with five achieving complete responses and zero serious side effects. No factory, no weeks of waiting; just a single IV infusion that reprograms the patient's own immune cells. Oppenheimer called it potentially best-in-class and flagged Legend as a takeover target in a space that's already seen $5 billion in M&A.
Read more →CRISPR Gene Therapy Approved for Two-Year-Olds With Sickle Cell Disease
The FDA expanded Casgevy's approval to children as young as two, making it the first gene therapy cleared for toddlers with sickle cell disease or beta thalassemia. In trials, every evaluable child went 12+ months without a severe pain crisis or blood transfusion. The approval took just 53 days, adding roughly 5,500 eligible patients in the U.S.
Read more →Pfizer's Oral Pill Hits Both Endpoints in Vitiligo, a First for the Condition
Ritlecitinib cleared both co-primary endpoints in two Phase 3 vitiligo trials, achieving significant facial and total-body repigmentation at both dose levels. No oral drug has ever been approved specifically for vitiligo, a condition affecting 1 in 100 to 200 people. Pfizer plans global regulatory filings, leveraging the drug's existing approval for alopecia areata.
Read more →Setbacks and Regulation
Novo's Anti-Inflammatory Heart Drug Crushed Its Biomarker, Then Flopped Anyway
Novo Nordisk's ziltivekimab reduced a key inflammation marker by 92% in earlier studies, but in a 6,300-patient Phase 3 trial, it performed identically to placebo on actual heart attacks and strokes (hazard ratio: 0.99). Jefferies called the result "strategically negative," reinforcing Novo's reliance on its GLP-1 obesity franchise. Two more trials in different patient populations are still running.
Read more →The FDA Just Built a Fast Lane for Drug Factories
Seven companies, including Lilly, Regeneron, and gene therapy startup Kriya Therapeutics, were selected for the FDA's new PreCheck pilot, which provides regulatory feedback on manufacturing facilities while they're still being built. The program could shave up to 14 months off approval timelines for complex biologics, quietly becoming one of the most consequential regulatory innovations in years.
Read more →